{{Rsnum
|rsid=11695471
|Gene=DNMT3A
|Chromosome=2
|position=25234839
|Orientation=plus
|GMAF=0.163
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=DNMT3A
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 15.9 | 38.1 | 46.0
| HCB | 0.0 | 18.6 | 81.4
| JPT | 0.0 | 34.1 | 65.9
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 18.6 | 81.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID|18381459|OA=1
}} 829 Caucasian cases with primary epithelial ovarian cancer and 941 frequency-matched unaffected controls 
Three SNPs in DNMT3A were associated with risk among multivitamin supplement users: 
*3' untranslated region (UTR) C>G ([[rs13420827]]: OR, 0.8; 95% CI, 0.6-1.0; P interaction = 0.006; FPRP = 0.54)
*intron 6 G>A ([[rs11887120]]: OR, 0.8; 95% CI, 0.7-1.0; P interaction = 0.007; FPRP = 0.57)
*intron 22 A>T ([[rs11695471]]: OR, 1.2; 95% CI, 1.0-1.5; P interaction = 0.01; FPRP = 0.66)

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}